Barbra J. Sasu

Atara Biotherapeutics (United States) — United States

Medicine · Health Sciences

22h-index1.9kcitations165works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(97), Biosimilars and Bioanalytical Methods(47), Monoclonal and Polyclonal Antibodies Research(35), Viral Infectious Diseases and Gene Expression in Insects(23), Iron Metabolism and Disorders(21)

Publications165 total

Figure FS4 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Supplementary Data 1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS7 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS3 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS6 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS2 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS5 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Data from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Table from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
393 DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors
Regular and Young Investigator Award Abstracts·2025Open Access
394 Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment
Regular and Young Investigator Award Abstracts·2025Open Access
Allogeneic CAR T Cell Therapy for Cancer
Annual Review of Cancer Biology·2023· 13 citedOpen Access
Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-Cell Lymphoma
Blood·2023· 3 cited
302 Generation of immune-evasive allogeneic CAR T cells by inactivation of the HLA transcriptional regulator RFX5 and disruption of the immune synapse
Regular and Young Investigator Award Abstracts·2023Open Access
279 Preclinical evaluation of allogeneic CD19 CAR T cells expressing an anti-rejection CD70 CAR
Regular and Young Investigator Award Abstracts·2023· 4 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Cesar Sommer(18), Thomas Van Blarcom(15), Javier Chaparro‐Riggers(14), Siler H. Panowski(12), Janette Sutton(11), Bijan Boldajipour(8), Tara Arvedson(7), Trevor Bentley(7), Julien Valton(7), Zea Melton(7), Hsin‐Yuan Cheng(7), Keegan S. Cooke(6), Graham Molineux(6), Román Galetto(6), Duy Nguyen(6), Thomas Pertel(5), Tao Sai(5), Surabhi Srinivasan(5), Silvia K. Tacheva-Grigorova(5), Yvonne S.L. Mak(5)